Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
Patent 5464854 Issued on November 7, 1995. Estimated Expiration Date: 
April 29, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 29, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for preventing or treating depression employing an ace inhibitor Method for preventing or treating anxiety employing an ACE inhibitor Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties Patent #: 5246943 InventorApplicationNo. 235468 filed on 04/29/1994US Classes:514/381, Tetrazoles (including hydrogenated)514/223.5, With additional active ingredient514/303, Exactly three ring nitrogens in the bicyclo ring system514/394, Benzo fused at 4,5-positions of the diazole ring514/397, Additional hetero ring514/417Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.)ExaminersPrimary: Jordan, KimberlyAttorney, Agent or FirmInternational ClassesA61K 031/54A61K 031/44 A61K 031/41 A61K 031/415 A61K 031/40 AbstractThe method of treatment moderating, blocking and/or eliminating premenstrual syndrome embodies the intermittent administering of an AT1 antagonist to a female having menstrual cycles characterized predominately by during substantially the luteal phase inclusive of at least one and frequently by two or more affective and/or autonomic and/or somatic symptoms of substantially incapacitating severity(ies) proximately substantially prior to menses of a menstrual cycle. Losartan is an example of an AT1 inhibitor and is administered either orally or parenterally continuously to a female during her menstrual cycle's luteal phase.Other References
Field of SearchExactly three ring nitrogens in the bicyclo ring systemTetrazoles (including hydrogenated) Benzo fused at 4,5-positions of the diazole ring Additional hetero ring With additional active ingredient Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.) | |
